doxorubicin,rituximab,polatuzumab vedotin,etoposide
roche,biogen,teva,sopherion
['polatuzumab vedotin', 'rituximab', 'hodgkin', 'lymphoma', 'doxorubicin']
dr. ryan lynch is presenting "polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (pola-da-epch-r) for upfront treatment of aggressive b-cell non-hodgkin lymphomas" at #asco22. 
Fred Hutch is pushing cancer and disease research forward — because every discovery is another step toward better, longer lives. #CuresStartHere